
    
      This is a Phase I, open-label, multi-center trial designed to evaluate the safety,
      tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with
      advanced/relapsed solid tumors. The following dosing schedule, consisting of 21-day treatment
      cycles, is being examined:

      Five days on/two days off on Days 1 to 5, 8 to 12, and 15 to 19 (5/2 schedule).
    
  